TY - JOUR
T1 - Chronic Neurology in COVID-19 Era
T2 - Clinical Considerations and Recommendations From the REPROGRAM Consortium
AU - Bhaskar, Sonu
AU - Bradley, Sian
AU - Israeli-Korn, Simon
AU - Menon, Bindu
AU - Chattu, Vijay Kumar
AU - Thomas, Pravin
AU - Chawla, Jasvinder
AU - Kumar, Rajeev
AU - Prandi, Paolo
AU - Ray, Daniel
AU - Golla, Sailaja
AU - Surya, Nirmal
AU - Yang, Harvey
AU - Martinez, Sandra
AU - Ozgen, Mihriban Heval
AU - Codrington, John
AU - González, Eva María Jiménez
AU - Toosi, Mandana
AU - Hariya Mohan, Nithya
AU - Menon, Koravangattu Valsraj
AU - Chahidi, Abderrahmane
AU - Mederer Hengstl, Susana
N1 - Publisher Copyright:
© Copyright © 2020 Bhaskar, Bradley, Israeli-Korn, Menon, Chattu, Thomas, Chawla, Kumar, Prandi, Ray, Golla, Surya, Yang, Martinez, Ozgen, Codrington, González, Toosi, Hariya Mohan, Menon, Chahidi and Mederer Hengstl.
PY - 2020/6/24
Y1 - 2020/6/24
N2 - With the rapid pace and scale of the emerging coronavirus 2019 (COVID-19) pandemic, a growing body of evidence has shown a strong association of COVID-19 with pre- and post- neurological complications. This has necessitated the need to incorporate targeted neurological care for this subgroup of patients which warrants further reorganization of services, healthcare workforce, and ongoing management of chronic neurological cases. The social distancing and the shutdown imposed by several nations in the midst of COVID-19 have severely impacted the ongoing care, access and support of patients with chronic neurological conditions such as Multiple Sclerosis, Epilepsy, Neuromuscular Disorders, Migraine, Dementia, and Parkinson disease. There is a pressing need for governing bodies including national and international professional associations, health ministries and health institutions to harmonize policies, guidelines, and recommendations relating to the management of chronic neurological conditions. These harmonized guidelines should ensure patient continuity across the spectrum of hospital and community care including the well-being, safety, and mental health of the patients, their care partners and the health professionals involved. This article provides an in-depth analysis of the impact of COVID-19 on chronic neurological conditions and specific recommendations to minimize the potential harm to those at high risk.
AB - With the rapid pace and scale of the emerging coronavirus 2019 (COVID-19) pandemic, a growing body of evidence has shown a strong association of COVID-19 with pre- and post- neurological complications. This has necessitated the need to incorporate targeted neurological care for this subgroup of patients which warrants further reorganization of services, healthcare workforce, and ongoing management of chronic neurological cases. The social distancing and the shutdown imposed by several nations in the midst of COVID-19 have severely impacted the ongoing care, access and support of patients with chronic neurological conditions such as Multiple Sclerosis, Epilepsy, Neuromuscular Disorders, Migraine, Dementia, and Parkinson disease. There is a pressing need for governing bodies including national and international professional associations, health ministries and health institutions to harmonize policies, guidelines, and recommendations relating to the management of chronic neurological conditions. These harmonized guidelines should ensure patient continuity across the spectrum of hospital and community care including the well-being, safety, and mental health of the patients, their care partners and the health professionals involved. This article provides an in-depth analysis of the impact of COVID-19 on chronic neurological conditions and specific recommendations to minimize the potential harm to those at high risk.
KW - chronic neurological disease
KW - coronavirus disease 2019 (COVID-19)
KW - guidelines
KW - healthcare services
KW - neurodegenerative disorders
KW - pandemics
KW - protocols
KW - recommendations
UR - http://www.scopus.com/inward/record.url?scp=85087878671&partnerID=8YFLogxK
U2 - 10.3389/fneur.2020.00664
DO - 10.3389/fneur.2020.00664
M3 - Article
SN - 1664-2295
VL - 11
JO - Frontiers in Neurology
JF - Frontiers in Neurology
M1 - 664
ER -